BIO-VIEW LTD |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 29 ILa | 0.00% |
|
+1.05% | -11.85% |
| 27/03 | Bio-View Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 27/03 | Bio-View Ltd announces an Equity Buyback for ILS 0.7 million worth of its shares. | CI |
| Sales 2022 | 29.14M 7.78M 2.91B 649M | Sales 2023 | 34.77M 9.28M 3.48B 774M | Capitalization | 45.53M 12.15M 4.55B 1.01B |
|---|---|---|---|---|---|
| Net income 2022 | - 0 0 0 | Net income 2023 | - 0 0 0 | EV / Sales 2022 | 1.21 x |
| Net cash position 2022 | 15.38M 4.1M 1.54B 342M | Net cash position 2023 | 13.61M 3.63M 1.36B 303M | EV / Sales 2023 | 0.92 x |
| P/E ratio 2022 |
87.6
x | P/E ratio 2023 |
116
x | Employees | 33 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 48.48% |
More Fundamentals
* Assessed data
More news
| 1 week | +1.05% | ||
| Current month | -1.69% | ||
| 1 month | -0.34% | ||
| 3 months | -9.09% | ||
| 6 months | -10.63% | ||
| Current year | -11.85% |
1 week
27.70
29.80
1 month
27.4031.00
Current year
27.4037.00
1 year
27.4040.00
3 years
27.4048.00
5 years
15.3049.70
10 years
15.3051.50
| Managers | Title | Age | Since |
|---|---|---|---|
Yuval Harari
FOU | Founder | 62 | 18/98/18 |
Alan Schwebel
CEO | Chief Executive Officer | 69 | 01/02/01 |
| Director of Finance/CFO | 41 | 01/20/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Emmanuel Gill
CHM | Chairman | 85 | 16/00/16 |
Oded Tamir
BRD | Director/Board Member | 68 | 28/22/28 |
Eliane Markowitz
BRD | Director/Board Member | 60 | 01/15/01 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 25/24/25 | 29 | 0.00% | 9 |
| 24/24/24 | 29 | +1.05% | 2,163 |
Delayed Quote TEL AVIV STOCK EXCHANGE, April 25, 2024 at 04:54 pm IST
More quotes
Bio View Ltd is an Israel-based laboratory equipment developer. The Company manufactures and assembles, markets and services an automated cell diagnostic system for use in cytology, cytogenetic, hematology and pathology laboratories. The workstation is called Duet, which provides automated detection, classification, analysis, and counting of cells for diagnosis and study. Additionally, Duet provides a method to analyze both the morphology and the genetic content of the same cell. The Company has applications in Cancer diagnosis and follow-up of minimal-residual disease (MRD); in pre-natal and post-natal Cytogenetic analyses in the analysis of sperm cells and rare-cell detection (RCD). In 2005, the Company introduced two new scanning workstations: the ALLEGRO, for automated scanning of Fluorescence in-situ Hybridization (FISH) probes without Brightfield scanning, and the ACCORD, for the semi-automated imaging of FISH for breast cancer (Her-2/Neu) and for FISH on tissue.
| 1st Jan change | Capi. | |
|---|---|---|
| -11.85% | 10M | |
| -12.42% | 19.08B | |
| -46.59% | 2.65B | |
| +17.50% | 1.87B | |
| -0.58% | 1.61B | |
| +25.36% | 1.21B | |
| -8.67% | 1.02B | |
| -21.91% | 905M | |
| -4.42% | 716M | |
| -17.51% | 682M |
- Stock Market
- Equities
- BIOV Stock
